Clinical Cancer Research
News
24 Jan 2021
Researchers at Kanazawa University report in Clinical Cancer Research that in the most common type of lung cancer, certain secondary mutations occurring with another gene alteration known as ALK make the efficacy of alectinib, an otherwise commonly used drug for treating lung cancer, become unfavorable. Combining alectinib with another kind of drug can overcome this adverse effect, however.
Events
Sorry, no events coming up for this topic.
Researchers
Sorry, no researchers coming up for this topic.
Giants in history
Sorry, no researchers coming up for this topic.